Affinage

Showing ABCC10 — MRP7 is a alias.

ABCC10

ATP-binding cassette sub-family C member 10 · UniProt Q5T3U5

Length
1492 aa
Mass
161.6 kDa
Annotated
2026-06-09
48 papers in source corpus 22 papers cited in narrative 23 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 8/8 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ABCC10/MRP7 is an ATP-dependent ABC efflux transporter that exports amphipathic anions and a broad spectrum of xenobiotics, thereby acting as an endogenous determinant of multidrug resistance (PMID:15256465, PMID:21576088). It is a 1492-residue protein with three membrane-spanning domains architecturally resembling other MRP family members (PMID:11146224), and it catalyzes MgATP-dependent transport of the model amphipathic anion E2 17βG with LTC4 as a potent competitive inhibitor; unlike MRP1/2, its transport activity is glutathione-independent (PMID:12527806, PMID:19118001). Substrate engagement (E2 17βG, LTC4, tamoxifen, taxanes, Ara-C) stimulates its BeFx-sensitive ATPase activity, and in polarized epithelia it localizes to the basolateral surface and exports docetaxel vectorially from the apical to basolateral side (PMID:23087055). Through this pump activity ABCC10 confers resistance to taxanes, vinca alkaloids, epothilone B, nucleoside analogues, and the kinase inhibitor gefitinib by reducing intracellular drug accumulation (PMID:15256465, PMID:19118001, PMID:30515095), and it additionally effluxes antiretroviral agents such as tenofovir and nevirapine (PMID:21628669, PMID:22082652). Knockout mouse studies establish its in vivo roles: Abcc10-null animals are hypersensitive to taxanes and exhibit altered tumor growth and metastasis (PMID:21576088, PMID:24937672), and ABCC10 also governs dietary fat absorption, with its deletion reducing intestinal triglyceride uptake and protecting against diet-induced obesity (PMID:36430292). More recently ABCC10 was shown to bind and efflux the STING agonist 2'3'-cGAMP at the R545 site, suppressing STING-TBK1-IRF3 signaling and conferring radiotherapy resistance (PMID:40770563). Its expression is controlled transcriptionally by FOXM1, which binds the ABCC10 promoter directly to drive 5-FU resistance (PMID:28051999), by the BRG1/SWI/SNF chromatin-remodeling complex, and post-transcriptionally via the FTO/YTHDF2 m6A axis (PMID:33563765). In drug-resistant cells the transporter redistributes from the plasma membrane to lysosomes, where it contributes to intracellular drug sequestration (PMID:37767694).

Mechanistic history

Synthesis pass · year-by-year structured walk · 18 steps
  1. 2001 Medium

    Established the basic molecular identity of ABCC10/MRP7 as a multidomain ABC transporter, providing the structural framework for all subsequent functional work.

    Evidence cDNA sequence analysis with in vitro translation in reticulocyte lysates and FISH chromosomal mapping

    PMID:11146224

    Open questions at the time
    • No transport substrate or function demonstrated
    • No experimental membrane topology validation
    • Protein product confirmed only in vitro, not in cells
  2. 2003 High

    Answered whether ABCC10 is a functional transporter by demonstrating MgATP-dependent transport of an amphipathic anion, defining its biochemical activity class.

    Evidence Membrane vesicle transport assays with kinetic and competitive inhibition analysis in transfected HEK293 cells

    PMID:12527806

    Open questions at the time
    • Physiological substrate unknown
    • Only modest LTC4 transport, scope of endogenous cargo undefined
    • No link to drug resistance yet
  3. 2004 High

    Connected ABCC10 transport activity to clinical drug resistance by showing it effluxes taxanes and vinca alkaloids, establishing it as a multidrug resistance transporter.

    Evidence Ectopic overexpression in HEK293 cells with cytotoxicity and radiolabeled paclitaxel accumulation assays

    PMID:15256465

    Open questions at the time
    • Overexpression context only, endogenous relevance not shown
    • Direct transport of taxanes in vesicles not measured here
    • No in vivo confirmation
  4. 2009 High

    Expanded the substrate range to nucleoside analogues and epothilone B and distinguished ABCC10 mechanistically from MRP1/2 by showing glutathione-independent transport.

    Evidence Transfected HEK293 cells and P-gp/Mrp1-deficient MEFs with cytotoxicity, accumulation, and BSO experiments

    PMID:19118001

    Open questions at the time
    • Co-substrate requirements (if any) not fully defined
    • Endogenous expression context still not addressed
  5. 2008 Medium

    Demonstrated that endogenously expressed ABCC10 drives paclitaxel efflux in lung cancer cells, moving beyond overexpression artifacts.

    Evidence siRNA knockdown and sulfinpyrazone inhibition in NSCLC cells with intracellular paclitaxel accumulation

    PMID:18445659

    Open questions at the time
    • Single cancer cell type
    • No in vivo validation in this study
  6. 2009 Medium

    Identified kinase inhibitors (EGFR and BCR-Abl TKIs) as functional reversal agents that inhibit ABCC10 efflux without altering its expression, defining a pharmacological resensitization strategy.

    Evidence Accumulation/efflux assays and Western blot in MRP7-transfected HEK293 cells

    PMID:19720054 PMID:19841739

    Open questions at the time
    • Binding site of inhibitors not mapped
    • Clinical translatability not tested
    • Single-lab observations
  7. 2008 Medium

    Characterized cepharanthine as a competitive ABCC10 inhibitor with defined kinetics, providing a chemical tool for dissecting transport function.

    Evidence Membrane vesicle E2 17βG competitive inhibition and paclitaxel accumulation assays in transfected cells

    PMID:19150344

    Open questions at the time
    • Specificity across other ABC transporters not established
    • No structural basis for inhibition
  8. 2011 High

    Provided the first in vivo genetic proof that Abcc10 is an endogenous determinant of taxane sensitivity and host toxicity.

    Evidence Abcc10-knockout mice and MEFs with in vivo paclitaxel treatment and pathological assessment

    PMID:21576088

    Open questions at the time
    • Tissue distribution of effect not fully mapped
    • Mechanism of bone marrow toxicity not dissected
  9. 2012 High

    Integrated ATPase reconstitution, vectorial transport, and basolateral localization, and added tamoxifen as a substrate, establishing the polarized export directionality of ABCC10.

    Evidence Crude membrane BeFx-sensitive ATPase assays and transepithelial docetaxel transport in polarized LLC-PK1 cells

    PMID:23087055

    Open questions at the time
    • Coupling stoichiometry of ATP hydrolysis to transport not quantified
    • Structural basis of substrate binding unknown
  10. 2011 Medium

    Showed ABCC10 effluxes antiretroviral drugs in immune cells, extending its pharmacological relevance to HIV therapy.

    Evidence Overexpression, cepharanthine inhibition, and siRNA knockdown in CD4+ cells and macrophages with accumulation assays for tenofovir and nevirapine

    PMID:21628669 PMID:22082652

    Open questions at the time
    • Direct vesicle transport of these drugs not measured
    • Clinical pharmacokinetic impact not established
  11. 2014 Medium

    Revealed an in vivo role beyond chemoresistance, linking Abcc10 to mammary tumor growth, apoptosis, and metastasis.

    Evidence Abcc10-null x MMTV-PyVmT mouse cross with allograft, migration, and docetaxel survival assays

    PMID:24937672

    Open questions at the time
    • Transported effector responsible for growth/metastasis phenotype not identified
    • Mechanism linking efflux to apoptosis unclear
  12. 2017 Medium

    Identified FOXM1 as a direct transcriptional driver of ABCC10, providing an upstream regulatory mechanism for resistance.

    Evidence ChIP for promoter binding, FOXM1 gain/loss-of-function, and ABCC10-inhibitor xenografts in colorectal cancer

    PMID:28051999

    Open questions at the time
    • Other transcriptional regulators not addressed here
    • Single lab
  13. 2018 Medium

    Defined gefitinib as an actively effluxed substrate, implicating ABCC10 in resistance to targeted EGFR therapy.

    Evidence In vitro transport assay with efflux ratio, overexpression, and xenografts in NSCLC

    PMID:30515095

    Open questions at the time
    • Endogenous loss-of-function not tested in this study
    • Kinetics of gefitinib transport not measured
  14. 2021 Medium

    Established post-transcriptional control of ABCC10 by the m6A machinery, showing FTO-mediated demethylation stabilizes ABCC10 mRNA to transfer drug resistance.

    Evidence Exosome internalization assays, m6A quantification, FTO and YTHDF2 manipulation, in vitro and in vivo resistance models

    PMID:33563765

    Open questions at the time
    • Specific m6A sites on ABCC10 mRNA not exhaustively mapped
    • Single lab
  15. 2022 Medium

    Uncovered a physiological metabolic role by showing Abcc10 governs dietary fat absorption and influences diet-induced obesity.

    Evidence Abcc10-knockout mice with plasma/intestinal lipid measurements and fat absorption assays

    PMID:36430292

    Open questions at the time
    • Direct lipid substrate transported by ABCC10 not identified
    • Molecular link between efflux and enterocyte fatty acid uptake unclear
  16. 2023 Medium

    Revealed that ABCC10 redistributes to lysosomes in resistant cells, contributing to intracellular drug sequestration as an alternative resistance mode.

    Evidence Confocal localization, siRNA knockdown, and flow cytometry for lysosomal drug accumulation in paclitaxel-resistant TNBC and NSCLC cells

    PMID:37767694

    Open questions at the time
    • Trafficking signals driving lysosomal relocalization unknown
    • Relative contribution vs plasma membrane efflux unquantified
  17. 2025 Medium

    Defined a novel immunomodulatory function by showing ABCC10 effluxes cGAMP at the R545 site to suppress STING signaling and confer radiotherapy resistance.

    Evidence CRISPR metabolic screen, vesicle transport, docking, ELISA, transcriptomics, and in vivo radiotherapy + nilotinib combination

    PMID:40770563

    Open questions at the time
    • R545 binding site predicted by docking, not structurally resolved
    • Single lab
    • Generality across tumor types not established
  18. 2025 Medium

    Implicated the BRG1/SWI/SNF chromatin-remodeling complex in enabling ABCC10 transcription and lysosomal drug sequestration.

    Evidence SMARCA4 siRNA, PFI3/ACBI1 SWI/SNF inhibition, and lysosomal drug distribution in resistant cancer cells (preprint)

    Open questions at the time
    • Preprint, not yet peer reviewed
    • Direct SWI/SNF occupancy at ABCC10 locus vs indirect effect not distinguished

Open questions

Synthesis pass · forward-looking unresolved questions
  • An experimentally determined structure of ABCC10 and direct validation of its substrate/inhibitor binding sites remain unresolved, limiting mechanistic understanding of how its broad substrate range maps onto the transport cycle.
  • No experimental cryo-EM/crystal structure (only an MRP1-based homology model exists)
  • Coupling of ATP hydrolysis to transport not quantified
  • How a single pump accommodates such chemically diverse substrates unexplained

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0005215 transporter activity 6 GO:0016787 hydrolase activity 2 GO:0140657 ATP-dependent activity 2
Localization
GO:0005886 plasma membrane 2 GO:0005764 lysosome 1
Pathway
R-HSA-1643685 Disease 5 R-HSA-382551 Transport of small molecules 5 R-HSA-9748784 Drug ADME 3

Evidence

Reading pass · 23 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2001 MRP7/ABCC10 is a 1492 amino acid ABC transporter with three membrane-spanning domains (structural architecture resembling MRP1/2/3/6), confirmed by synthesis of an ~158 kDa protein in reticulocyte lysates programmed with the MRP7 cDNA, and maps to chromosome 6p12-21. cDNA sequence analysis, reticulocyte lysate in vitro translation, fluorescence in situ hybridization Cancer letters Medium 11146224
2003 ABCC10/MRP7 mediates MgATP-dependent transport of the amphipathic anion 17β-estradiol-17β-D-glucuronide (E2 17βG) with Km ~57.8 µM and Vmax ~53.1 pmol/mg/min in membrane vesicles; LTC4 is a potent competitive inhibitor (Ki ~1.5 µM), and the pump shows modest LTC4 transport but not other canonical MRP substrates tested. Membrane vesicle transport assay using HEK293 cells transfected with MRP7 expression vector; competitive inhibition kinetics Molecular pharmacology High 12527806
2004 ABCC10/MRP7 overexpression in HEK293 cells confers resistance to docetaxel (9–13-fold), paclitaxel (3-fold), vincristine (3-fold), and vinblastine (3–4-fold); MRP7-transfected cells show reduced accumulation of radiolabeled paclitaxel, consistent with ATP-dependent efflux pump activity. Ectopic expression in HEK293 cells, cytotoxicity assays, radiolabeled drug accumulation assay Cancer research High 15256465
2009 ABCC10/MRP7 confers resistance to nucleoside analogues (cytarabine/Ara-C, gemcitabine, 2',3'-dideoxycytidine, PMEA) and epothilone B in addition to taxanes and vinca alkaloids; buthionine sulfoximine did not attenuate MRP7-conferred resistance, indicating MRP7-mediated transport does not involve glutathione (unlike MRP1/2). MRP7-transfected HEK293 cells and mouse embryo fibroblasts deficient in P-gp and Mrp1; cytotoxicity and radiolabeled drug accumulation assays Cancer research High 19118001
2011 Abcc10 knockout mice show that Abcc10 is an endogenous resistance factor in vivo: Abcc10−/− mouse embryo fibroblasts are hypersensitive to docetaxel, paclitaxel, vincristine, and Ara-C with increased drug accumulation; Abcc10−/− mice treated with paclitaxel exhibit increased lethality with neutropenia and bone marrow/spleen/thymus toxicity. Abcc10−/− mouse generation, MEF cytotoxicity/accumulation assays, in vivo paclitaxel treatment with pathological assessment Cancer research High 21576088
2012 ABCC10 substrates E2 17βG and LTC4 stimulate ABCC10 BeFx-sensitive ATPase activity; tamoxifen is identified as a novel substrate and ATPase stimulator; docetaxel, paclitaxel, and Ara-C also increase basal ATPase activity. ABCC10 localizes to the basolateral cell surface and exports docetaxel from apical to basolateral side in transepithelial LLC-PK1 assays. Sorafenib and cepharanthine inhibit ABCC10 docetaxel transport activity. Crude membrane ATPase assays with BeFx (vanadate-sensitive controls), transepithelial well assay in ABCC10-overexpressing LLC-PK1 cells, radiolabeled docetaxel transport Cancer research High 23087055
2008 Sulfinpyrazone (an ABCC10 inhibitor) alters sensitivity to paclitaxel in ABCC10-expressing NSCLC cells concomitant with increased intracellular paclitaxel accumulation; siRNA knockdown of ABCC10 enhances paclitaxel cytotoxicity in NCI-H23 cells with increased intracellular paclitaxel, confirming ABCC10 effluxes paclitaxel endogenously in lung cancer cells. siRNA knockdown in NSCLC cells, pharmacological inhibition with sulfinpyrazone, intracellular paclitaxel accumulation assay Molecular cancer therapeutics Medium 18445659
2009 Lapatinib and erlotinib (EGFR TKIs) reverse MRP7/ABCC10-mediated multidrug resistance by inhibiting drug efflux function (increased intracellular [3H]-paclitaxel accumulation and decreased efflux in MRP7-transfected cells) without altering MRP7 protein expression levels. MRP7-transfected HEK293 cells, cytotoxicity assay, [3H]-paclitaxel accumulation and efflux assays, Western blot Biochemical pharmacology Medium 19720054
2009 Imatinib and nilotinib (BCR-Abl TKIs) reverse MRP7/ABCC10-mediated multidrug resistance by inhibiting paclitaxel efflux and increasing intracellular [3H]-paclitaxel accumulation in MRP7-transfected HEK293 cells, without altering MRP7 expression. MRP7-transfected HEK293 cells, MTT assay, [3H]-paclitaxel accumulation and efflux assays, Western blot PloS one Medium 19841739
2008 Cepharanthine reverses MRP7/ABCC10-mediated paclitaxel resistance and competitively inhibits E2 17βG transport by MRP7 in membrane vesicle assays with a Ki of 4.86 µM, identifying it as a competitive inhibitor of ABCC10. MRP7-transfected HEK293 cells, paclitaxel accumulation/efflux assays, membrane vesicle E2 17βG transport competitive inhibition assay Biochemical pharmacology Medium 19150344
2011 Tenofovir (TFV) is a substrate for ABCC10: TFV accumulation is 35% lower in HEK293-ABCC10 cells than parental HEK293 cells, reversed by cepharanthine; siRNA knockdown of ABCC10 increases TFV accumulation in CD4+ cells (18%) and monocyte-derived macrophages (25%). ABCC10-transfected HEK293 cells, pharmacological inhibition with cepharanthine, siRNA knockdown in primary CD4+ cells and macrophages, drug accumulation assay The Journal of infectious diseases Medium 21628669
2012 Nevirapine is a substrate for ABCC10: accumulation is 37% lower in HEK293-ABCC10 cells vs. parental, reversed by cepharanthine; siRNA knockdown increases nevirapine accumulation in CD4+ cells (32%) and monocyte-derived macrophages (38%). ABCC10-transfected HEK293 cells, siRNA knockdown in CD4+ cells and macrophages, drug accumulation assays, pharmacological inhibition Pharmacogenetics and genomics Medium 22082652
2017 FOXM1 promotes 5-FU resistance in colorectal cancer by directly binding to the ABCC10 promoter and driving its transcription; ABCC10 inhibition reverses FOXM1-induced 5-FU resistance in vivo. Chromatin immunoprecipitation (promoter binding), FOXM1 overexpression and silencing in CRC cells, in vivo xenograft with ABCC10 inhibitor Oncotarget Medium 28051999
2018 ABCC10 actively effluxes gefitinib with an efflux ratio of 7.8 in an in vitro transport assay; overexpression of ABCC10 reduces intracellular gefitinib accumulation and decreases gefitinib sensitivity in NSCLC cells and xenograft models. In vitro transport assay, ABCC10-overexpressing cell lines, intracellular gefitinib accumulation measurement, in vivo xenograft Frontiers in pharmacology Medium 30515095
2021 Exosomal delivery of the m6A demethylase FTO from gefitinib-resistant cells to recipient cells decreases m6A modification on ABCC10 mRNA, reducing YTHDF2-mediated decay and thereby increasing ABCC10 expression, which mediates gefitinib resistance transfer. Exosome internalization assays, m6A quantification, FTO knockdown/overexpression, YTHDF2 functional studies, in vitro and in vivo resistance models Molecular cancer research Medium 33563765
2014 Abcc10 loss in MMTV-PyVmT mammary tumor mice results in faster tumor growth with reduced apoptosis and reduced metastasis; Abcc10-null tumor-derived cell lines are less migratory; Abcc10−/− mice show increased survival upon docetaxel treatment, confirming in vivo role as docetaxel resistance factor in mammary tumors. Abcc10−/− x MMTV-PyVmT mouse cross, allograft and cellular assays, migration assays, in vivo docetaxel treatment survival analysis British journal of cancer Medium 24937672
2021 ABCC10 homology model (based on cryo-EM structure of MRP1) combined with molecular dynamics simulations and docking identifies predicted substrate- and modulator-binding sites within the transmembrane region of MRP7/ABCC10, with motion patterns consistent with the ABC efflux mechanism. Homology modeling based on MRP1 cryo-EM structure, molecular dynamics simulation, in silico docking MedComm Low 34766143
2022 LXRα activation by its agonist TO901317 alters ABCC10 gene expression in rat hepatic and cardiac tissues, identifying ABCC10 as a specific LXRα target gene. In vivo rat hypercholesterolemia model, LXRα agonist treatment, hepatic/cardiac gene expression analysis Biochemical and biophysical research communications Low 35462094
2023 ABCC10 redistributes from plasma membrane to lysosomes in paclitaxel-resistant cancer cells; lysosome-localized ABCC10 (along with ABCC3 and ABCC5) contributes to sequestration of doxorubicin and paclitaxel-OregonGreen488 in lysosomes; siRNA silencing of ABCC10 limits lysosomal drug accumulation. Western blot and confocal microscopy for localization, siRNA knockdown, ABCC inhibitors, flow cytometry for drug accumulation in lysosomes in paclitaxel-resistant TNBC and NSCLC cells Cellular physiology and biochemistry Medium 37767694
2023 ABCC10 regulates glucosylceramide (GlcCer) synthesis and efflux differentially: sorafenib (ABCC10 inhibitor) decreases both GlcCer synthesis and efflux, while cepharanthine reduces only GlcCer efflux but not synthesis, in Huh-7 liver cells. Pharmacological inhibition with sorafenib and cepharanthine, GlcCer synthesis and efflux measurement in Huh-7 cells Nutrients Low 36678216
2022 ABCC10 deletion in mice results in lower plasma and intestinal triglycerides (~38% and 36% reduction), ameliorates diet-induced obesity, reduces oleate uptake by enterocytes (~25–30%), and reduces intestinal triglyceride absorption (~37%), indicating ABCC10 regulates dietary fat absorption. Abcc10 knockout mice, plasma/intestinal lipid measurements, insulin/glucose tolerance tests, intestinal fat absorption assays International journal of molecular sciences Medium 36430292
2025 ABCC10 binds and effluxes 2'3'-cyclic GMP-AMP (cGAMP) in an ATP-dependent manner at the R545 site; ABCC10-mediated cGAMP export suppresses the STING-TBK1-IRF3 signaling pathway, reducing RT-induced ROS and DNA damage, thereby conferring radiotherapy resistance. Nilotinib (ABCC10 inhibitor) combined with radiotherapy synergistically inhibits tumor growth in vivo. CRISPR metabolic library screen, vesicle transport assay, molecular docking, ELISA for cGAMP, RNA transcriptomics, ABCC10 overexpression and silencing, in vivo tumor radiotherapy + nilotinib combination Cell death and differentiation Medium 40770563
2025 BRG1 (SMARCA4)-containing SWI/SNF chromatin remodeling complex enables transcription of ABCC10 (along with ABCC3 and ABCC5); pharmacological inhibition (PFI3) or PROTAC degradation (ACBI1) of SWI/SNF, or BRG1 siRNA silencing, substantially reduces ABCC10 transcription and reverses lysosomal drug sequestration in paclitaxel-resistant cancer cells. SMARCA4 siRNA knockdown, PFI3/ACBI1 pharmacological SWI/SNF inhibition, ABCC10 gene expression, lysosomal drug distribution in paclitaxel-resistant TNBC and NSCLC cells bioRxivpreprint Medium

Source papers

Stage 0 corpus · 48 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2004 Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer research 157 15256465
2001 Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily. Cancer letters 155 11146224
2003 Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Molecular pharmacology 148 12527806
2006 ABCC10, ABCC11, and ABCC12. Pflugers Archiv : European journal of physiology 113 16868766
2009 Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer research 105 19118001
2012 Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. Cancer letters 95 23063650
2011 Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. The Journal of infectious diseases 87 21628669
2009 Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochemical pharmacology 81 19720054
2008 MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer. Molecular cancer therapeutics 73 18445659
2009 ABCC10/MRP7 is associated with vinorelbine resistance in non-small cell lung cancer. Oncology reports 61 19082471
2009 Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10). PloS one 61 19841739
2008 Cepharanthine is a potent reversal agent for MRP7(ABCC10)-mediated multidrug resistance. Biochemical pharmacology 60 19150344
2011 Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-/-) mice. Cancer research 57 21576088
2017 FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10. Oncotarget 56 28051999
2021 Exosomal Delivery of FTO Confers Gefitinib Resistance to Recipient Cells through ABCC10 Regulation in an m6A-dependent Manner. Molecular cancer research : MCR 48 33563765
2012 Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer research 48 23087055
2013 Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs. Chinese journal of cancer 41 24103790
2015 BAG3-mediated miRNA let-7g and let-7i inhibit proliferation and enhance apoptosis of human esophageal carcinoma cells by targeting the drug transporter ABCC10. Cancer letters 39 26655271
2018 ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC. Frontiers in pharmacology 38 30515095
2013 Reversal of MRP7 (ABCC10)-mediated multidrug resistance by tariquidar. PloS one 35 23393594
2017 The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors. Molecular cancer therapeutics 33 28265007
2013 Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug resistance protein 7 (ABCC10). Oncology reports 32 23525656
2015 The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study. Oncotarget 31 25402202
2012 Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenetics and genomics 30 22082652
2014 PD173074, a selective FGFR inhibitor, reverses MRP7 (ABCC10)-mediated MDR. Acta pharmaceutica Sinica. B 26 26579384
2014 Abcc10 status affects mammary tumour growth, metastasis, and docetaxel treatment response. British journal of cancer 23 24937672
2019 Genetic variation in the ATP binding cassette transporter ABCC10 is associated with neutropenia for docetaxel in Japanese lung cancer patients cohort. BMC cancer 22 30890141
2024 The role of ABCC10/MRP7 in anti-cancer drug resistance and beyond. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 19 38330827
2021 A Novel miR-98 Negatively Regulates the Resistance of Endometrial Cancer Cells to Paclitaxel by Suppressing ABCC10/MRP-7. Frontiers in oncology 18 34950596
2014 Synthesis and biological evaluation of pentacyclic strychnos alkaloids as selective modulators of the ABCC10 (MRP7) efflux pump. Journal of medicinal chemistry 17 25419978
2013 bba, a synthetic derivative of 23-hydroxybutulinic acid, reverses multidrug resistance by inhibiting the efflux activity of MRP7 (ABCC10). PloS one 15 24069321
2021 Insights on the structure-function relationship of human multidrug resistance protein 7 (MRP7/ABCC10) from molecular dynamics simulations and docking studies. MedComm 12 34766143
2009 [Expression and Clinical Significance of ABCC10 in the Patients with Non-small Cell Lung Cancer.]. Zhongguo fei ai za zhi = Chinese journal of lung cancer 11 20719174
2022 Intense endoplasmic reticulum stress (ERS) / IRE1α enhanced Oxaliplatin efficacy by decreased ABCC10 in colorectal cancer cells. BMC cancer 8 36585626
2021 Enhancement of anticancer drug sensitivity in multidrug resistance cells overexpressing ATP-binding cassette (ABC) transporter ABCC10 by CP55, a synthetic derivative of 5-cyano-6-phenylpyrimidin. Experimental cell research 8 34246653
2023 Activity of Lysosomal ABCC3, ABCC5 and ABCC10 is Responsible for Lysosomal Sequestration of Doxorubicin and Paclitaxel-Oregongreen488 in Paclitaxel-Resistant Cancer Cell Lines. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 6 37767694
2021 CMP25, a synthetic new agent, targets multidrug resistance-associated protein 7 (MRP7/ABCC10). Biochemical pharmacology 4 34126072
2023 Differential Regulation of Glucosylceramide Synthesis and Efflux by Golgi and Plasma Membrane Bound ABCC10. Nutrients 3 36678216
2022 Effect of activation of liver X receptor alpha on cardiac & hepatic ABCC10 and SLC17A5 drug transporters in hypercholesterolemic rat model. Biochemical and biophysical research communications 3 35462094
2017 E2F site in the essential promoter region does not confer S phase-specific transcription of the ABCC10 gene in human prostate cancer cells. Acta biochimica Polonica 3 28612064
2025 ABCC1 and ABCC10 as predictive biomarkers of docetaxel treatment response in prostate cancer. Current research in pharmacology and drug discovery 2 40213361
2023 let-7g sensitized liver cancer cells to 5-fluorouracil by downregulating ABCC10 expression. Chemical biology & drug design 2 38054583
2022 Genetic variations in the ATP-binding cassette transporter ABCC10 are associated with neutropenia in Japanese patients with lung cancer treated with nanoparticle albumin-bound paclitaxel. Investigational new drugs 2 35759133
2022 ATP-Binding Cassette Protein ABCC10 Deficiency Prevents Diet-Induced Obesity but Not Atherosclerosis in Mice. International journal of molecular sciences 2 36430292
2025 ABCC10-mediated cGAMP efflux drives cancer cell radiotherapy resistance. Cell death and differentiation 1 40770563
2014 Identification of a human ABCC10 orthologue in Catharanthus roseus reveals a U12-type intron determinant for the N-terminal domain feature. Journal of genetics 1 24840820
2025 ABCB1 and ABCC10 polymorphisms predict sensitivity to first- and third-generation EGFR-TKIs in EGFR-mutant NSCLC. Investigational new drugs 0 41343113
2011 [Alternative splicing of an ATP-binding cassette transporter ABCC10 in Tetrahymena thermophila]. Dong wu xue yan jiu = Zoological research 0 22184018

Missed literature

Know a paper Affinage missed for ABCC10? Flag it for the maintainers and the community.

No submissions yet.